GERRESHEIMER AG

Gerresheimer AG discloses a voting‑rights announcement and a short‑sale position, revealing recent shareholder activity and market sentiment in the life‑sciences sector.

Gerresheimer AG’s stock is under intense short‑selling pressure, revealing market doubts and volatility; explore why investors are watching this healthcare player.

Gerresheimer AG’s plunge: accounting scandals, debt restructuring, and a rejected €41 takeover bid leave investors wary, showing how missteps erode value.

Gerresheimer AG faces investor uncertainty after delayed 2025 reports, a postponed shareholder meeting, credit talks, and the sale of its U.S. unit—yet its specialty glass business still holds long‑term growth potential.

Gerresheimer AG Aktie sinkt um 3 % nach Berichtverschiebung: Analysten senken Kursziele, „Hold"-Bewertung bleibt – jetzt potenziell unterbewertet?

Gerresheimer AG’s shares appear “stable” after Oddo’s nod, yet tariff worries, a weak SDAX and rising short‑selling hint at hidden volatility. Discover how to navigate this uncertain outlook for the pharma‑packaging specialist.

Gerresheimer AG corrects 2024 earnings after BaFin flags Bill‑and‑Hold revenue misstatement, cutting earnings per share and prompting a sharp stock drop.

Gerresheimer AG revises 2024 earnings by €28 m after BaFin audit, yet shares stay steady and a Buy rating is maintained.

Gerresheimer AG’s share jump after JPMorgan’s 8.5% stake shows if a mid‑cap packaging firm can truly rebound—or if it’s a short‑term rally.

Gerresheimer AG’s 65 % plunge reveals leadership turmoil, BaFin probes, and repeated profit warnings – what this means for investors and the future of medical packaging stocks.